News
Biogen Canada Inc. is disappointed by INESSS's recommendation against listing SKYCLARYS™ (omaveloxolone), despite its therapeutic potential for individuals living with Friedreich ataxia (FA) — a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback